Fox Run Management’s Emergent Biosolutions EBS Stock Holding History

Fox Run Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-28,020	Closed	-$136K	–	956
2025 Q1	$136K	Buy	+28,020	New	+$232K	0.02%	842
2024 Q3	–	Sell	-11,039	Closed	-$75.3K	–	873
2024 Q2	$75.3K	Buy	+11,039	New	+$47.5K	0.01%	732
2021 Q4	–	Sell	-7,460	Closed	-$374K	–	527
2021 Q3	$374K	Buy	+7,460	New	+$452K	0.24%	162
2020 Q4	–	Sell	-2,657	Closed	-$275K	–	212
2020 Q3	$275K	Buy	+2,657	New	+$286K	0.69%	54
2018 Q2	–	Sell	-12,782	Closed	-$673K	–	729
2018 Q1	$673K	Buy	12,782 +5,128	+67%	+$256K	0.16%	209
2017 Q4	$356K	Buy	+7,654	New	+$322K	0.1%	406

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Fox Run Management's EBS Position: Q2 2025 in Review

Fox Run Management sold out of Emergent Biosolutions (EBS) in Q2 2025, closing a stake of 28,020 shares — an estimated $136K sold.

Fox Run Management first reported a position in EBS in Q4 2017 and held it in 6 quarters. The position peaked at $673K in Q1 2018. 161 funds tracked by Wall St. Rank hold EBS as of Q2 2025.

Fox Run Management reported no remaining Emergent Biosolutions position as of Q2 2025 after selling out during the quarter.
Fox Run Management sold 28,020 Emergent Biosolutions shares in Q2 2025, an estimated $136K.
Fox Run Management first reported a position in Emergent Biosolutions in Q4 2017 and held it in 6 quarters.
Fox Run Management's Emergent Biosolutions position peaked at $673K in Q1 2018.
161 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.